There are several potential COVID-19 vaccines currently in the development pipeline, each providing either passive or active immunity to SARS-CoV-2 via different immunological mechanisms.

Join us for the sixth in our COVID-19 Webinar Series to discuss:

• How do these vaccines work? What is their mechanism of action?
• How do we advance promising therapies through pre-clinical testing and then ensure fast, efficient testing in the clinical setting?
• What is the most likely timeline for a COVID-19 vaccine from R&D to market access?
• Most of these therapies will reach the market via accelerated regulatory pathways with limited evidence of efficacy. How do we ensure that they remain safe and effective?

Panelists:

• Richard Day, (Moderator) Professor of Clinical Pharmacology, University of New South Wales and St Vincent's Hospital, Australia
• Keith Chirgwin, Deputy Director, Regulatory Affairs, Bill & Melinda Gates Foundation
• Philip R. Dormitzer, Vice President and Chief Scientific Officer: Viral Vaccines, Pfizer Vaccine Research and Development
• Julie Gerberding, Executive Vice President and Chief Patient Officer, Merck
• Joshua Liang, Chief Strategy Officer, Clover Biopharmaceuticals